PMID- 38356609
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240216
IS  - 2405-8440 (Print)
IS  - 2405-8440 (Electronic)
IS  - 2405-8440 (Linking)
VI  - 10
IP  - 3
DP  - 2024 Feb 15
TI  - Prognostic impact of coexisting cardiovascular disease in patients with cancer: A 
      multicenter retrospective cohort study.
PG  - e25594
LID - 10.1016/j.heliyon.2024.e25594 [doi]
LID - e25594
AB  - BACKGROUND: The incidence of malignancy and cardiovascular disease (CVD) is 
      increasing worldwide. However, it is not entirely clear how the coexistence of 
      CVD at the time of cancer diagnosis affects the overall survival of patients with 
      cancer. METHODS AND RESULTS: We used the cancer registries and administrative 
      claims data of patients diagnosed with cancer at 36 designated cancer care 
      hospitals in Osaka, Japan, from 2010 to 2015. The Cox proportional hazard model 
      was used to examine how coexisting CVD (heart failure [HF], ischemic heart 
      disease, peripheral arterial disease, cerebrovascular accidents, and atrial 
      fibrillation) affected overall survival and the impact of HF severity, as 
      documented by the New York Heart Association (NYHA) classification. Of the 
      131,701 patients with cancer, 9704 had coexisting CVD. The 3-year survival rates 
      for patients with and without coexisting CVD were 62.9 % and 77.6 %, 
      respectively. The adjusted hazard ratio (aHR) for all-cause mortality for 
      coexisting CVD was 1.47 (95 % confidence interval, 1.41-1.52). Among the CVD 
      subtype, patients with coexisting HF had the poorest prognosis. The aHRs in 
      patients with HF by NYHA classification, using the patients without HF as a 
      reference, were as follows: Class I: 1.33 (p = 0.217); II: 1.68 (p < 0.001); III: 
      1.54 (p = 0.011); IV: 2.47 (p < 0.001). CONCLUSION: Coexisting CVD and HF 
      severity at cancer diagnosis is associated with survival in patients with cancer.
CI  - (c) 2024 The Authors.
FAU - Kuwabara, Yoshihiro
AU  - Kuwabara Y
AD  - Cancer Control Center, Osaka International Cancer Institute, 3-1-69 Otemae, 
      Chuo-ku, Osaka, 541-8567, Japan.
FAU - Morishima, Toshitaka
AU  - Morishima T
AD  - Cancer Control Center, Osaka International Cancer Institute, 3-1-69 Otemae, 
      Chuo-ku, Osaka, 541-8567, Japan.
FAU - Kudo, Haruka
AU  - Kudo H
AD  - Cancer Control Center, Osaka International Cancer Institute, 3-1-69 Otemae, 
      Chuo-ku, Osaka, 541-8567, Japan.
FAU - Ma, Chaochen
AU  - Ma C
AD  - Cancer Control Center, Osaka International Cancer Institute, 3-1-69 Otemae, 
      Chuo-ku, Osaka, 541-8567, Japan.
FAU - Kato, Mizuki Shimadzu
AU  - Kato MS
AD  - Cancer Control Center, Osaka International Cancer Institute, 3-1-69 Otemae, 
      Chuo-ku, Osaka, 541-8567, Japan.
FAU - Koyama, Shihoko
AU  - Koyama S
AD  - Cancer Control Center, Osaka International Cancer Institute, 3-1-69 Otemae, 
      Chuo-ku, Osaka, 541-8567, Japan.
FAU - Nakata, Kayo
AU  - Nakata K
AD  - Cancer Control Center, Osaka International Cancer Institute, 3-1-69 Otemae, 
      Chuo-ku, Osaka, 541-8567, Japan.
FAU - Tabuchi, Takahiro
AU  - Tabuchi T
AD  - Cancer Control Center, Osaka International Cancer Institute, 3-1-69 Otemae, 
      Chuo-ku, Osaka, 541-8567, Japan.
FAU - Miyashiro, Isao
AU  - Miyashiro I
AD  - Cancer Control Center, Osaka International Cancer Institute, 3-1-69 Otemae, 
      Chuo-ku, Osaka, 541-8567, Japan.
LA  - eng
PT  - Journal Article
DEP - 20240205
PL  - England
TA  - Heliyon
JT  - Heliyon
JID - 101672560
PMC - PMC10865314
OTO - NOTNLM
OT  - Cancer
OT  - Coexisting cardiovascular disease
OT  - Heart failure
OT  - Survival
COIS- The authors declare the following financial interests/personal relationships 
      which may be considered as potential competing interests:Toshitaka Morishima 
      reports financial support was provided by the 10.13039/501100001691Japan Society 
      for the Promotion of Science, Japan. Isao Miyashiro reports financial support was 
      provided by the 10.13039/501100001691Japan Society for the Promotion of Science. 
      Isao Miyashiro reports financial support was provided by the 
      10.13039/100009647Ministry of Health, Japan, Labour, and Welfare.
EDAT- 2024/02/15 06:42
MHDA- 2024/02/15 06:43
PMCR- 2024/02/05
CRDT- 2024/02/15 03:58
PHST- 2023/08/25 00:00 [received]
PHST- 2023/12/01 00:00 [revised]
PHST- 2024/01/30 00:00 [accepted]
PHST- 2024/02/15 06:43 [medline]
PHST- 2024/02/15 06:42 [pubmed]
PHST- 2024/02/15 03:58 [entrez]
PHST- 2024/02/05 00:00 [pmc-release]
AID - S2405-8440(24)01625-6 [pii]
AID - e25594 [pii]
AID - 10.1016/j.heliyon.2024.e25594 [doi]
PST - epublish
SO  - Heliyon. 2024 Feb 5;10(3):e25594. doi: 10.1016/j.heliyon.2024.e25594. eCollection 
      2024 Feb 15.